| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10046591 | HBV | ENSG00000022355.18 | protein_coding | GABRA1 | No | No | 2554 | P14867 |
| TVIS30082845 | HIV | ENSG00000022355.18 | protein_coding | GABRA1 | No | No | 2554 | P14867 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GABRA1 |
|---|---|
| DrugBank ID | DB00402 |
| Drug Name | Eszopiclone |
| Target ID | BE0004797 |
| UniProt ID | Q9UN88 |
| Regulation Type | positive allosteric modulator |
| PubMed IDs | 19698408; 8241608; 25817320 |
| Citations | Doble A, Canton T, Malgouris C, Stutzmann J, Piot O, Bardone M, Pauchet C, Blanchard J: The mechanism of action of zopiclone. Eur Psychiatry. 1995;10 Suppl 3:117s-28s. doi: 10.1016/0924-9338(96)80093-9.@@Wadworth AN, McTavish D: Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging. 1993 Sep-Oct;3(5):441-59. doi: 10.2165/00002512-199303050-00006.@@Dixon CL, Harrison NL, Lynch JW, Keramidas A: Zolpidem and eszopiclone prime alpha1beta2gamma2 GABAA receptors for longer duration of activity. Br J Pharmacol. 2015 Jul;172(14):3522-36. doi: 10.1111/bph.13142. Epub 2015 May 11. |
| Groups | Approved; Investigational |
| Direct Classification | Cyclopyrrolones |
| SMILES | CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1 |
| Pathways | |
| PharmGKB | PA162630444 |
| ChEMBL | CHEMBL1522 |
« Prev123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163Next »
